Ovarian clear cell carcinoma

Beryl Manning-Geist; Sushmita Gordhandas; Preetha Ramalingam; Oliver Zivanovic

doi:10.1016/B978-0-323-82938-0.00004-5

Ovarian clear cell carcinoma

Beryl Manning-Geist, Sushmita Gordhandas, Preetha Ramalingam, Oliver Zivanovic

Pathology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

In the United States, it is estimated that there will be 21,410 new diagnoses of ovarian cancer, and 13,770 deaths from ovarian cancer. Ovarian clear cell carcinoma represents 5% to 10% of ovarian cancers in the United States. Ovarian clear cell carcinoma is a rare ovarian malignancy; as a result, clinical trials are not powered to make conclusions for ovarian clear cell carcinoma despite known differences in response to treatment. Recommendations for surveillance and treatment of ovarian clear cell carcinoma are nonspecific and follow recommendations for the most common histology of high-grade serous ovarian cancer. In this chapter, we will highlight the known distinct features of ovarian clear cell carcinoma and treatment recommendations.

Original language	English (US)
Title of host publication	Diagnosis and Treatment of Rare Gynecologic Cancers
Publisher	Elsevier
Pages	55-76
Number of pages	22
ISBN (Electronic)	9780323829380
ISBN (Print)	9780323829397
DOIs	https://doi.org/10.1016/B978-0-323-82938-0.00004-5
State	Published - Jan 1 2023

Keywords

ARID1A
CA125
Chemotherapy
Endometriosis
Epithelial ovarian cancer
Ovarian clear cell carcinoma
Radiation therapy
Surgery

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-82938-0.00004-5

Cite this

@inbook{06e70812e63b4a47986df4022afa9672,

title = "Ovarian clear cell carcinoma",

abstract = "In the United States, it is estimated that there will be 21,410 new diagnoses of ovarian cancer, and 13,770 deaths from ovarian cancer. Ovarian clear cell carcinoma represents 5% to 10% of ovarian cancers in the United States. Ovarian clear cell carcinoma is a rare ovarian malignancy; as a result, clinical trials are not powered to make conclusions for ovarian clear cell carcinoma despite known differences in response to treatment. Recommendations for surveillance and treatment of ovarian clear cell carcinoma are nonspecific and follow recommendations for the most common histology of high-grade serous ovarian cancer. In this chapter, we will highlight the known distinct features of ovarian clear cell carcinoma and treatment recommendations.",

keywords = "ARID1A, CA125, Chemotherapy, Endometriosis, Epithelial ovarian cancer, Ovarian clear cell carcinoma, Radiation therapy, Surgery",

author = "Beryl Manning-Geist and Sushmita Gordhandas and Preetha Ramalingam and Oliver Zivanovic",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-82938-0.00004-5",

language = "English (US)",

isbn = "9780323829397",

pages = "55--76",

booktitle = "Diagnosis and Treatment of Rare Gynecologic Cancers",

publisher = "Elsevier",

}

TY - CHAP

T1 - Ovarian clear cell carcinoma

AU - Manning-Geist, Beryl

AU - Gordhandas, Sushmita

AU - Ramalingam, Preetha

AU - Zivanovic, Oliver

PY - 2023/1/1

Y1 - 2023/1/1

N2 - In the United States, it is estimated that there will be 21,410 new diagnoses of ovarian cancer, and 13,770 deaths from ovarian cancer. Ovarian clear cell carcinoma represents 5% to 10% of ovarian cancers in the United States. Ovarian clear cell carcinoma is a rare ovarian malignancy; as a result, clinical trials are not powered to make conclusions for ovarian clear cell carcinoma despite known differences in response to treatment. Recommendations for surveillance and treatment of ovarian clear cell carcinoma are nonspecific and follow recommendations for the most common histology of high-grade serous ovarian cancer. In this chapter, we will highlight the known distinct features of ovarian clear cell carcinoma and treatment recommendations.

AB - In the United States, it is estimated that there will be 21,410 new diagnoses of ovarian cancer, and 13,770 deaths from ovarian cancer. Ovarian clear cell carcinoma represents 5% to 10% of ovarian cancers in the United States. Ovarian clear cell carcinoma is a rare ovarian malignancy; as a result, clinical trials are not powered to make conclusions for ovarian clear cell carcinoma despite known differences in response to treatment. Recommendations for surveillance and treatment of ovarian clear cell carcinoma are nonspecific and follow recommendations for the most common histology of high-grade serous ovarian cancer. In this chapter, we will highlight the known distinct features of ovarian clear cell carcinoma and treatment recommendations.

KW - ARID1A

KW - CA125

KW - Chemotherapy

KW - Endometriosis

KW - Epithelial ovarian cancer

KW - Ovarian clear cell carcinoma

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85152338477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152338477&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-82938-0.00004-5

DO - 10.1016/B978-0-323-82938-0.00004-5

M3 - Chapter

AN - SCOPUS:85152338477

SN - 9780323829397

SP - 55

EP - 76

BT - Diagnosis and Treatment of Rare Gynecologic Cancers

PB - Elsevier

ER -

Ovarian clear cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this